Overview
Arrowhead Pharmaceuticals is a clinical-stage and commercial-stage biopharmaceutical company headquartered in Pasadena, California, focused on developing RNA interference (RNAi) therapeutics to target genes and silence disease-causing pathways. The company leverages its proprietary TRiM™ platform to address therapeutic areas including cardiometabolic diseases (hypertriglyceridemia, cardiovascular disease, obesity), pulmonary conditions (idiopathic pulmonary fibrosis, inflammatory diseases), liver disease, and neuromuscular disorders. Arrowhead's mission centers on translating RNAi science into transformative medicines for patients with previously intractable diseases, with multiple candidates in clinical development and one approved product (plozasiran/REDEMPLO®) for familial chylomicronemia syndrome.